Abstract:Background: Despite the introduction of targeted therapies, most patients with myeloid malignancies will not be cured and progress. Genomics is useful to elucidate the mutational landscape but remains limited in the prediction of therapeutic outcome and identification of targets for resistance. Dysregulation of phosphorylation-based signaling pathways is a hallmark of cancer, and therefore, kinase-inhibitors are playing an increasingly important role as targeted treatments. Untargeted phosphoproteomics analysis pipelines have been published but show limitations in inferring kinase-activities and identifying potential biomarkers of response and resistance. Methods: We developed a phosphoproteomics workflow based on titanium dioxide phosphopeptide enrichment with subsequent analysis by liquid chromatography tandem mass spectrometry (LC-MS). We applied a novel Kinase-Activity Enrichment Analysis (KAEA) pipeline on differential phosphoproteomics profiles, which is based on the recently published SetRank enrichment algorithm with reduced false positive rates. Kinase activities were inferred by this algorithm using an extensive reference database comprising five experimentally validated kinase-substrate meta-databases complemented with the NetworKIN in-silico prediction tool. For the proof of concept, we used human myeloid cell lines (K562, NB4, THP1, OCI-AML3, MOLM13 and MV4-11) with known oncogenic drivers and exposed them to clinically established kinase-inhibitors. Results: Biologically meaningful over- and under-active kinases were identified by KAEA in the unperturbed human myeloid cell lines (K562, NB4, THP1, OCI-AML3 and MOLM13). To increase the inhibition signal of the driving oncogenic kinases, we exposed the K562 (BCR-ABL1) and MOLM13/MV4-11 (FLT3-ITD) cell lines to either Nilotinib or Midostaurin kinase inhibitors, respectively. We observed correct detection of expected direct (ABL, KIT, SRC) and indirect (MAPK) targets of Nilotinib in K562 as well as indirect (PRKC, MAPK, AKT, RPS6K) targets of Midostaurin in MOLM13/MV4-11, respectively. Moreover, our pipeline was able to characterize unexplored kinase-activities within the corresponding signaling networks. Conclusions: We developed and validated a novel KAEA pipeline for the analysis of differential phosphoproteomics MS profiling data. We provide translational researchers with an improved instrument to characterize the biological behavior of kinases in response or resistance to targeted treatment. Further investigations are warranted to determine the utility of KAEA to characterize mechanisms of disease progression and treatment failure using primary patient samples.

Systems-level reconstruction of kinase phosphosignaling networks regulating endothelial barrier integrity using temporal data

Exploiting polypharmacology to dissect host kinases and kinase inhibitors that modulate endothelial barrier integrity

Evaluating signaling pathway inference from kinase-substrate interactions and phosphoproteomics data

Dynamic probabilistic threshold networks to infer signaling pathways from time-course perturbation data

Homologous control of protein signaling networks

Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring

Inferring Catalysis in Biological Systems

Augmented Sparse Reconstruction of Protein Signaling Networks

Knowledge-Based Analysis for Detecting Key Signaling Events from Time-Series Phosphoproteomics Data

A Mechanistic Systems Biology Model of Brain Microvascular Endothelial Cell Signaling Reveals Dynamic Pathway-Based Therapeutic Targets for Brain Ischemia

Systematically Studying Kinase Inhibitor Induced Signaling Network Signatures by Integrating Both Therapeutic and Side Effects.

phuEGO: A network-based method to reconstruct active signalling pathways from phosphoproteomics datasets

Inferring the Sign of Kinase-Substrate Interactions by Combining Quantitative Phosphoproteomics with a Literature-Based Mammalian Kinome Network

Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA)

Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis

Mapping Complex Networks: Exploring Boolean Modeling of Signal Transduction Pathways

Structural modeling and analysis of signaling pathways based on Petri nets.

The Logic of EGFR/ErbB Signaling: Theoretical Properties and Analysis of High-Throughput Data

Proteomic Sensors for Quantitative, Multiplexed and Spatial Monitoring of Kinase Signaling

Perturbation Biology: Inferring Signaling Networks in Cellular Systems

Systems-level identification of PKA-dependent signaling in epithelial cells